Katie Weigel
Family Medicine · Waterloo, IANPI 1689291411
Payments from drug & device makers
Across 157 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$780
- Pfizer$281
- Lilly USA, LLC$255
- Boehringer Ingelheim$220
- Biohaven Pharmaceutical Holding Company Ltd.$137
- Idorsia Pharmaceuticals US Inc$98
- plus $521 from 12 others
What the payments were for
- Food & beverage$2,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $780 |
| Pfizer | 16 | $281 |
| Lilly USA, LLC | 15 | $255 |
| Boehringer Ingelheim | 12 | $220 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $137 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Novo Nordisk | 4 | $80 |
| Bayer | 4 | $78 |
| AstraZeneca | 5 | $66 |
| Amgen | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Exact Sciences | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Harmony Biosciences LLC | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,293 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,032 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,709 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,473 |
| Irbesartan | 32 | $496 |
| Omeprazole | 22 | $477 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $392 |
| Diclofenac Sodium | 26 | $355 |
| Rosuvastatin Calcium | 20 | $331 |
| Levothyroxine Sodium | 33 | $298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $296 |
| Ropinirole Hcl | 21 | $216 |
| Gabapentin | 21 | $196 |
| Pantoprazole Sodium | 26 | $177 |
| Tamsulosin Hcl | 14 | $165 |
| Memantine Hcl | 12 | $158 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Waterloo
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Garold MoyerWaterloo$53K
- Matthew SmithWaterloo$25K
- Gregory HarterWaterloo$14K
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.